ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志

• 论文 • 上一篇    下一篇

TAM受体酪氨酸激酶与肾脏疾病

  

  • 出版日期:2020-02-28 发布日期:2020-03-19

TAM receptor tyrosine kinases and kidney diseases

  • Online:2020-02-28 Published:2020-03-19

摘要:

TAM(TYRO3、AXL、MER)受体酪氨酸激酶(TAMRTKs)属广泛表达的受体酪氨酸激酶亚家族,在细胞增殖、生存、迁移、胞葬、炎症及免疫调控、血小板稳定等多方面发挥重要功能。动物模型研究发现,肾脏局部或全身的TAMRTKs功能异常广泛参与Thy1肾小球肾炎、糖尿病肾病、抗肾小球基膜肾炎、单侧输尿管梗阻、肾毒性血清肾炎、急性肾损伤、高血压肾损伤等肾脏疾病的发病机制中。此外,肾脏TAMRTKs及循环中分泌型TAMRTKs的水平同狼疮性肾炎、糖尿病肾病、慢性肾脏病等疾病严重程度存在关联,有望成为新型疾病分子标志物。TAMRTKs亦参与慢性肾脏病相关血管粥样硬化及钙化的过程中。本文将对TAMRTKs在肾脏疾病中的研究进展进行综述。
 

Abstract: The TAM (TYRO3,AXL,MER) receptor tyrosine kinases (RTKs) belongs to the RTKs subfamilies,playing pivotal roles in cell proliferation,survival,migration,efferocytosis,inflammation/immune regulation and platelet stabilization.Evidence based on animal models indicate that dysfunction of renal or systemic TAMRTKs may involve in pathogenesis of kidney diseases including Thy1 glomerulonephritis,diabetic nephropathy,antiglomerular basement membrane nephritis,unilateral ureteral obstruction,nephrotoxic serum nephritis,acute kidney injury and hypertensive renal damage.The increased levels of renal TAMRTKs and circulating secreted TAMRTKs in patients with lupus nephritis,diabetic nephropathy and chronic kidney disease (CKD) correlate with the disease severity,making TAMRTKs to be promising new biomarkers.TAMRTKs also participate in CKDinduced atherosclerosis and vascular calcification.This article reviews roles of TAMRTKs in kidney diseases.